TRUEBLUE
Trueblue, after having announced the integration of its Artificial Intelligence Relationship Management with Microsoft Dynamics 365 and Power Platform, officially launches on the market:
AiDEA is the new AI driven Omnichannel Customer Engagement suite. The foundation of the solution, represented by Artificial Intelligence , integrates and powers the operational and analytical functionalities based on Microsoft Dynamics 365 and Power Platform , for a holistic and integrated experience, with the goal of revolutionizing the working model of Pharma & Life Science markets, simplifying omni-channel engagement through intuitive and conversational interaction.
Two fundamental components guide the change, whose union had not yet materialized in the reference market: the concrete integration of Big Data in the perspective of Multichannel Management and the use of Artificial Intelligence functionalities and algorithms. The latter is an element that can no longer be postponed from an IT point of view, as it is necessary to drive Customer Engagement processes to satisfy company objectives from both a strategic and an operational point of view.
These elements require a structural change in the approach of organizations and tools, as a generic Customer Relationship Management system is no longer sufficient. It is in fact necessary to adopt specific Smart Omnichannel Customer Engagement solutions, fully enabled in terms of Artificial Intelligence, to have, in a quick, simple and intuitive way, precise indications about one's own customers.
As part of this transition in fact, Pharma companies such as Angelini Pharma , Alfasigma and others are taking this direction with strength and determination with the aim of innovating and achieving their business results faster.
"Artificial Intelligence represents a tremendous opportunity to increase our effectiveness and we want to provide this competitive advantage to our employees thanks to AiDEA" said Pierluigi Antonelli, CEO of Angelini Pharma "After a long and thorough analysis, we identified Trueblue and Microsoft as the best partners to advance our Customer Engagement capabilities by delivering an innovative digital CRM solution that transforms strategy into action.”
Trueblue , which has always been at the center of technological and digital innovation for the pharmaceutical industry, thanks to the integration with Microsoft introduces with AiDEA a new paradigm in which Artificial Intelligence is the backbone and key factor of the evolutionary process.
"Through this integration, Trueblue will help companies in the industry accelerate their growth and find new ways to drive Digital Innovation through a wide range of solutions that will enable them to simplify the use of AI in their daily activities," said Marco Bonesini CEO of Trueblue
“In today’s reality of accelerated digital transformation processes, pharma & life science companies rely on proactive solutions such as AIDEA, integrated with Dynamics 365 and Power Platform, to enable effective omnichannel strategies” said Elena Bonfiglioli, Managing Director, HealthCare and Life Sciences, EMEA Regional Lead.
Discover more About Trueblue
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005610/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom